期刊文献+

氯诺昔康的不良反应及其合理使用的回顾性调查 被引量:16

A Retrospective Study of Adverse Drug Reaction and Rational Use of Lornoxicam
下载PDF
导出
摘要 目的:了解住院患者服用氯诺昔康(可塞风)的疗效、药物不良反应,促进临床合理使用。方法:回顾性观察使用氯诺昔康的29例住院患者,评价其止痛效果、药物不良反应发生及合理用药。结果:29例疼痛患者使用氯诺昔康后止痛效果确切,疼痛缓解率为100%。发生药物不良反应2例,药物不良反应发生率为6.90%;药物不良反应的发生与年龄大、合并用药不合理有关。不合理用药9例,发生率为31.03%,主要问题为用法、用量不当及合并用药不当。结论:氯诺昔康在临床上应用于镇痛,疗效确切,但要注意合理用药,避免不当的合并用药。 Objective:To study the rate of adverse drug reaction(ADR) and the rational use of lornoxicam among in-patients.Methods:All in-patients treated with lornoxicam in department of oncology in our hospital were retrospectively observed.Results:The overall efficacy of lornoxicam on pain lysis was 100%. Of 29 patients 4 ADR cases were found with a ADR rate was 6.90%. The ADR occurrence was related to older age and irrational drug use. 9 cases(31.03%) were related with irrational drug use, mainly irrational drug regimen and irrational drug combination. Conclusion:Lornoxicam is safe in clinical use, but attention should be paid on drug adverse reaction and rational use, particularly in the irrational drug combination.
出处 《中国药业》 CAS 2003年第12期67-68,共2页 China Pharmaceuticals
关键词 氯诺昔康 不良反应 合理用药 回顾性调查 Lornoxicam Adverse Drug Reaction Rational Drug Use Retrospective Study
  • 相关文献

参考文献5

二级参考文献17

  • 1[1]Pruss TP, Stroissnig H, Radhofer-Welte S, et al. Overview of the pharmacological properties, Pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J. 1990,66 (Suppl4):S 18-21
  • 2[2]Olkkola KT, Brunetto AV, Mattila MJ. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet, 1994, 26:107-120
  • 3[3]Kullich W, Klein G. Influence of the nonsteroidal anti-inflammatory drug lornoxicam in on the secretion of the endogenous opiate peptides dynorphin and β-endorphin. Aktuel Rheumatol, 1992, 17:128-132
  • 4[4]Detlef ER, Morten A, Dietmar S. A comparison of patientcontrolled analgesia with lornoxicam versus morphine in patients undergoing lumbar disk surgery. Anesth Analg. 1998,86:1045-1050
  • 5[5]Ilias W, Jansen M. Pain control after hysterectomy: an observer-blind, randomised trial of lornoxicam versus tramadol.Br J Clin Pract, 1996, 50:197-202
  • 6[6]Ronald D. Miller. Anesthesia. Fifth edition. Beijing: Science Press, Harcourt Asia, Churchill Livingstone, 2001. 334
  • 7[7]Berg J, Christoph T, Widerna M, et al. Isoenzyme-specific cyclooxygenase inhibitors: a whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line Mono Mac 6. J Pharmacol Toxicol Methods, 1997, 37;179-186
  • 8[8]Nuutinen LS, Laitinen JO, Salomaki TE. A risk-benefit appraisal of injectable NSAIDs in the management of postoperative pain. Drug Safety, 1993, 9:380-393
  • 9[9]Ilder-Smith CH, Bettiga A. The analgesic tramadol has minimal effect on gastrointestinal motor function. Br J Clin Pharmacol, 1997,43:71
  • 10Pruss TP,Stoiβnig H,Radhofer Welte S,et al.Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam[].Postgraduate Medical Journal.1990

共引文献220

同被引文献100

引证文献16

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部